Advent Capital Management’s Pfizer PFE Stock Holding History

Advent Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-369	Closed	-$1K	–	480
2015 Q4	$1K	Buy	+369	New	+$11.6K	﹤0.01%	457

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Advent Capital Management's PFE Position: Q1 2024 in Review

Advent Capital Management sold out of Pfizer (PFE) in Q1 2024, closing a stake of 100,000 shares — an estimated $2.88M sold.

Advent Capital Management first reported a position in PFE in Q2 2014 and held it in 14 quarters. The position peaked at $4.9M in Q1 2020. 2,874 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

Advent Capital Management reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
Advent Capital Management sold 100,000 Pfizer shares in Q1 2024, an estimated $2.88M.
Advent Capital Management first reported a position in Pfizer in Q2 2014 and held it in 14 quarters.
Advent Capital Management's Pfizer position peaked at $4.9M in Q1 2020.
2,874 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Advent Capital Management's 13F filing for Q1 2024, filed 14 May 2024.